References of "Ludwig, H"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEpidemiological and nonclinical studies investigating effects of iron in carcinogenesis-A critical review
Beguin, Yves ULg; Aapro, M.; Ludwig, H. et al

in Critical Reviews in Oncology/Hematology (2014), 89

The efficacy and tolerability of intravenous (i.v.) iron in managing cancer-related anemia and iron deficiency has been clinically evaluated and reviewed recently. However, long-term data in cancer ... [more ▼]

The efficacy and tolerability of intravenous (i.v.) iron in managing cancer-related anemia and iron deficiency has been clinically evaluated and reviewed recently. However, long-term data in cancer patients are not available; yet, long-term i.v. iron treatment in hemodialysis patients is not associated with increased cancer risk. This review summarizes epidemiological and nonclinical data on the role of iron in carcinogenesis. In humans, epidemiological data suggest correlations between certain cancers and increased iron exposure or iron overload. Nonclinical models that investigated whether iron can enhance carcinogenesis provide only limited evidence relevant for cancer patients since they were typically based on high iron doses as well as injection routes and iron formulations which are not used in the clinical setting. Nevertheless, in the absence of long-term outcome data from prospectively defined trials in i.v. iron-treated cancer patients, iron supplementation should be limited to periods of concomitant anti-tumor treatment. [less ▲]

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailPlasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Fernández de Larrea, C; Kyle, RA; Durie, BG et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2013), 27(4), 780-91

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailPrevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron
Aapro, M.; Osterborg, A.; Gascon, P. et al

in Annals of Oncology (2012), 23

Background: Chronic diseases reduce the availability of iron for effective erythropoiesis. This review summarises clinical consequences of iron deficiency (ID) and anaemia in cancer patients, mechanisms ... [more ▼]

Background: Chronic diseases reduce the availability of iron for effective erythropoiesis. This review summarises clinical consequences of iron deficiency (ID) and anaemia in cancer patients, mechanisms how impaired iron homeostasis affects diagnosis and treatment of ID, and data from clinical trials evaluating i.v. iron with or without concomitant erythropoiesis-stimulating agents (ESAs). Design: Clinical trial reports were identified in PubMed and abstracts at relevant major congresses. Results: Reported prevalence of ID in cancer patients ranges from 32 to 60% and most iron-deficient patients are also anaemic. Randomised clinical trials have shown superior efficacy of i.v. iron over oral or no iron in reducing blood transfusions, increasing haemoglobin, and improving quality of life in ESA-treated anaemic cancer patients. Furthermore, i.v. iron without additional ESA should be evaluated as potential treatment in patients with chemotherapyinduced anaemia. At recommended doses, i.v. iron is well tolerated, particularly compared with oral iron. No serious drug-related adverse effects were seen during long-term use in renal disease and no effect on tumour growth has been observed in trials with anaemic cancer patients. Conclusions: Reliable diagnosis and treatment of ID are recommended key steps in modern cancer patient management to minimise impact on quality of life and performance status. [less ▲]

Detailed reference viewed: 40 (1 ULg)
Full Text
Peer Reviewed
See detailRecombinant Interferon alfa-2c versus polychemotherapy (VMCP) for treatment of multiple myeloma : a prospective randomized trial
Ludwig, H.; Cortelezzi, A.; Scheithauer, W. et al

in European Journal of Cancer & Clinical Oncology (1986), 22

Detailed reference viewed: 9 (0 ULg)